title: Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.
abstract: We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.
authors.affiliation: Department of Internal Medicine, Hôpital Bichat, Paris, France. veronique.joly@bch.ap-hop-paris.fr
authors.forename: V
authors.initials: V
authors.lastname: Joly
authors.forename: M
authors.initials: M
authors.lastname: Moroni
authors.forename: E
authors.initials: E
authors.lastname: Concia
authors.forename: A
authors.initials: A
authors.lastname: Lazzarin
authors.forename: B
authors.initials: B
authors.lastname: Hirschel
authors.forename: J
authors.initials: J
authors.lastname: Jost
authors.forename: F
authors.initials: F
authors.lastname: Chiodo
authors.forename: Z
authors.initials: Z
authors.lastname: Bentwich
authors.forename: W C
authors.initials: WC
authors.lastname: Love
authors.forename: D A
authors.initials: DA
authors.lastname: Hawkins
authors.forename: E G
authors.initials: EG
authors.lastname: Wilkins
authors.forename: A J
authors.initials: AJ
authors.lastname: Gatell
authors.forename: N
authors.initials: N
authors.lastname: Vetter
authors.forename: C
authors.initials: C
authors.lastname: Greenwald
authors.forename: W W
authors.initials: WW
authors.lastname: Freimuth
authors.forename: W
authors.initials: W
authors.lastname: de Cian
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D020008:Delavirdine / Q000627:therapeutic use*; D004311:Double-Blind Method; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D016896:Treatment Outcome; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine; D020008:Delavirdine; D054303:HIV Reverse Transcriptase